Fig. 5
From: Using genetically encoded fluorescent biosensors to interrogate ovarian cancer metabolism
HyPer-expressing PDOs reflect clinical chemoresistance to carboplatin. A Schematic of study design. B Organoids derived from patient ascites were established and transfected with HyPer, and expression was confirmed using fluorescence microscopy. Scale bars = 200 um. C HyPer measurements following carboplatin treatment for 48 hours (n = 2 replicates for each patient). D The mean fold-change in Hyper signal in PDOs after carboplatin treatment was significantly greater in organoids from carboplatin-resistant patients (p < 0.01)